Sunmax Biotechnology , Ltd. EBIT

The latest EBIT for 4728.TWO is $1.3B as of June 2026. That compares with $980M in the prior-year period — up 28.2% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Sunmax Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4728.TWO's EBIT moved from $980M to $1.3B — a 28.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sunmax Biotechnology , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 4728.TWO currently prints $1.3B for EBIT, while the sector average sits near $99B. That is roughly 98.7% below the sector mean. Large gaps often invite a closer look at Sunmax Biotechnology , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $1.3B for 4728.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting 4728.TWO's EBIT ($1.3B), review year-over-year change from $980M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.